Patents Assigned to Molecular Insight Pharmaceuticals
  • Patent number: 7052913
    Abstract: In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L-amino acid decarboxylase is encapsulated and implanted in the brain to convert L-dopa to dopamine for treatment of Parkinson's disease.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: May 30, 2006
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Jon Zubieta, Grant Bonavia
  • Publication number: 20060093552
    Abstract: One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluoresence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium and rhenium complexes are also described. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
    Type: Application
    Filed: February 14, 2005
    Publication date: May 4, 2006
    Applicant: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John Babich, William Eckelman, Kevin Maresca, John Valliant, Jon Zubieta
  • Publication number: 20060078495
    Abstract: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more of the novel imaging agents of the invention.
    Type: Application
    Filed: November 16, 2005
    Publication date: April 13, 2006
    Applicant: Molecular Insight Pharmaceuticals, Inc.
    Inventor: David Elmaleh
  • Patent number: 7005119
    Abstract: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more of the novel imaging agents of the invention.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: February 28, 2006
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventor: David R. Elmalch
  • Publication number: 20060034758
    Abstract: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the radionuclide complexes are also described. Another aspect of the invention relates to imidazolyl and pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
    Type: Application
    Filed: February 14, 2005
    Publication date: February 16, 2006
    Applicant: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John Babich, Kevin Maresca, James Kronauge